115 related articles for article (PubMed ID: 36150914)
1. Underscreening, overscreening, and guideline-adherent cervical cancer screening in a national cohort.
Lee YW; Morgan JR; Fiascone S; Perkins RB
Gynecol Oncol; 2022 Nov; 167(2):181-188. PubMed ID: 36150914
[TBL] [Abstract][Full Text] [Related]
2. Cervical Cancer Screening Guideline Adherence Before and After Guideline Changes in Pennsylvania Medicaid.
Parekh N; Donohue JM; Men A; Corbelli J; Jarlenski M
Obstet Gynecol; 2017 Jan; 129(1):66-75. PubMed ID: 27926644
[TBL] [Abstract][Full Text] [Related]
3. Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort.
Mills JM; Morgan JR; Dhaliwal A; Perkins RB
Gynecol Oncol; 2021 Aug; 162(2):308-314. PubMed ID: 34090706
[TBL] [Abstract][Full Text] [Related]
4. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.
Datta SD; Koutsky LA; Ratelle S; Unger ER; Shlay J; McClain T; Weaver B; Kerndt P; Zenilman J; Hagensee M; Suhr CJ; Weinstock H
Ann Intern Med; 2008 Apr; 148(7):493-500. PubMed ID: 18378945
[TBL] [Abstract][Full Text] [Related]
6. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
[No Abstract] [Full Text] [Related]
8. Prevalence and determinants of cervical cancer screening with a combination of cytology and human papillomavirus testing.
Fokom Domgue J; Cunningham SA; Yu RK; Shete S
Ann Epidemiol; 2019 Aug; 36():40-47. PubMed ID: 31320153
[TBL] [Abstract][Full Text] [Related]
9. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
10. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
[TBL] [Abstract][Full Text] [Related]
11. Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
Qin J; Shahangian S; Saraiya M; Holt H; Gagnon M; Sawaya GF
Gynecol Oncol; 2021 Nov; 163(2):378-384. PubMed ID: 34507826
[TBL] [Abstract][Full Text] [Related]
12. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
13. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
Tiews S; Steinberg W; Schneider W; Hanrath C
J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
15. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
16. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
17. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
18. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
Fontham ETH; Wolf AMD; Church TR; Etzioni R; Flowers CR; Herzig A; Guerra CE; Oeffinger KC; Shih YT; Walter LC; Kim JJ; Andrews KS; DeSantis CE; Fedewa SA; Manassaram-Baptiste D; Saslow D; Wender RC; Smith RA
CA Cancer J Clin; 2020 Sep; 70(5):321-346. PubMed ID: 32729638
[TBL] [Abstract][Full Text] [Related]
20. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]